BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9740952)

  • 1. Update in glaucoma: the new pharmacotherapies. Brimonidine versus apraclonidine.
    Crichton AC
    Can J Ophthalmol; 1998 Aug; 33(5):254-5; discussion 257-8. PubMed ID: 9740952
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
    Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
    Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery.
    Chen TC
    J Cataract Refract Surg; 2005 Sep; 31(9):1707-12. PubMed ID: 16246772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy.
    Gordon RN; Liebmann JM; Greenfield DS; Lama P; Ritch R
    Eye (Lond); 1998; 12 ( Pt 4)():697-700. PubMed ID: 9850267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans.
    Schadlu R; Maus TL; Nau CB; Brubaker RF
    Arch Ophthalmol; 1998 Nov; 116(11):1441-4. PubMed ID: 9823343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selectivity of site of action and systemic effects of topical alpha agonists.
    Robin AL; Burnstein Y
    Curr Opin Ophthalmol; 1998 Apr; 9(2):30-3. PubMed ID: 10180510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of brimonidine allergy in patients previously allergic to apraclonidine.
    Williams GC; Orengo-Nania S; Gross RL
    J Glaucoma; 2000 Jun; 9(3):235-8. PubMed ID: 10877374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of acute topical administration of clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2% on visual field parameters and ocular perfusion pressure in patients with primary open-angle glaucoma.
    Sebastiani A; Parmeggiani F; Costagliola C; Ciancaglini M; D'Oronzo E; Mastropasqua L
    Acta Ophthalmol Scand Suppl; 2002; 236():29-30. PubMed ID: 12390124
    [No Abstract]   [Full Text] [Related]  

  • 9. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers.
    Mungan NK; Wilson TW; Nischal KK; Koren G; Levin AV
    J AAPOS; 2003 Feb; 7(1):69-70. PubMed ID: 12690374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More than just an ocular solution.
    Pekdemir M; Yanturali S; Karakus G
    Emerg Med J; 2005 Oct; 22(10):753-4. PubMed ID: 16189050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures.
    Chevrier RL; Assalian A; Duperré J; Lesk MR
    Ophthalmic Surg Lasers; 1999 Mar; 30(3):199-204. PubMed ID: 10100253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Alpha-2 adrenergic agonists in the treatment of glaucoma].
    Apătăchioae I; Chiseliţă D
    Oftalmologia; 1999; 47(2):35-40. PubMed ID: 10641099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy.
    Shin DH; Glover BK; Cha SC; Kim YY; Kim C; Nguyen KD
    Am J Ophthalmol; 1999 May; 127(5):511-5. PubMed ID: 10334342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure to topical apraclonidine in children with glaucoma.
    Wright TM; Freedman SF
    J Glaucoma; 2009; 18(5):395-8. PubMed ID: 19525731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brimonidine and apraclonidine as vasoconstrictors in adjustable strabismus surgery.
    Dahlmann-Noor AH; Cosgrave E; Lowe S; Bailly M; Vivian AJ
    J AAPOS; 2009 Apr; 13(2):123-6. PubMed ID: 19393510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is brimonidine ophthalmic a safe therapy for infants?
    Daubert GP
    J Clin Pharm Ther; 2006 Jun; 31(3):289-92. PubMed ID: 16789995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy.
    Yuen NS; Cheung P; Hui SP
    Jpn J Ophthalmol; 2005; 49(2):89-92. PubMed ID: 15838723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost].
    Gebhardt DO
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):275. PubMed ID: 10086159
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacological advances in the treatment of glaucoma.
    Serle JB
    Drugs Aging; 1994 Sep; 5(3):156-70. PubMed ID: 7803944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
    Mundorf T; Williams R; Whitcup S; Felix C; Batoosingh A
    J Ocul Pharmacol Ther; 2003 Feb; 19(1):37-44. PubMed ID: 12648302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.